Comparing Organon & Co. (NYSE:OGN) & DocGo (NASDAQ:DCGO)

Organon & Co. (NYSE:OGN) and DocGo (NASDAQ:DCGO) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, dividends, valuation and earnings.

Analyst Recommendations

This is a summary of recent ratings for Organon & Co. and DocGo, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	1	2	2	1	2.50
DocGo	0	3	3	0	2.50

Organon & Co. presently has a consensus target price of $18.00, suggesting a potential upside of 97.91%. DocGo has a consensus target price of $3.59, suggesting a potential upside of 122.29%. Given DocGo’s higher possible upside, analysts plainly believe DocGo is more favorable than Organon & Co..

Profitability

This table compares Organon & Co. and DocGo’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Organon & Co.	11.15%	163.88%	6.99%
DocGo	-4.20%	-3.26%	-2.24%

Valuation & Earnings

This table compares Organon & Co. and DocGo”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.40 billion	0.37	$864.00 million	$2.69	3.38
DocGo	$616.55 million	0.26	$19.99 million	($0.19)	-8.50

Organon & Co. has higher revenue and earnings than DocGo. DocGo is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Organon & Co. has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, DocGo has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500.

Insider & Institutional Ownership

77.4% of Organon & Co. shares are held by institutional investors. Comparatively, 56.4% of DocGo shares are held by institutional investors. 2.0% of Organon & Co. shares are held by company insiders. Comparatively, 3.8% of DocGo shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Organon & Co. beats DocGo on 10 of the 14 factors compared between the two stocks.

About Organon & Co.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

About DocGo

DocGo Inc. provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services. It also offers mobile health services through its platform that are performed at home, offices, and other locations; event services, which include on-site healthcare support at sporting events and concerts; and total care management solutions comprising healthcare services and ancillary services, such as shelter. DocGo Inc. was founded in 2015 and is headquartered in New York, New York.